



**LMA International NV**

**4 May 2009**

## **Announcement to the Singapore Exchange**

UPDATE ON PATENT INFRINGEMENT LITIGATION ACTIVITY

### **GERMAN COURT UPHOLDS LMA'S IP IN GERMANY**

Mainboard-listed LMA International NV ("LMA") would like to announce that on 28 April 2009, the German Federal Patent Court upheld its German intellectual property right – Utility Model DE 299 24 738 – against a challenge by Ambu A/S, and awarded LMA three quarters of its costs. Ambu had appealed against the earlier ruling by the German Patent Office on the validity of LMA's Utility Model.

The Utility Model protects LMA's invention of a reinforced tip on supraglottic airway devices, and is the subject of LMA's patent infringement action against Ambu in Germany. In that action, the German Court ruled in LMA's favour and Ambu is also appealing the German Court's decision.

Commenting on these latest developments, Lawrence Kinet, LMA's CEO, said: "This is an important outcome for us and we are very pleased with the Court's decision. The upholding of the Utility Model means that our action in Germany remains in force pending reinstatement on appeal of our European distal rib patent. It also clears the way for our damages claim for infringement of the Utility Model to now proceed."

The ruling of the German Federal Patent Court does not affect the actions against Ambu in the Netherlands and France, which remain suspended pending reinstatement on appeal of the European distal rib patent.

#### **LMA International NV**

Osprey House, Old Street, St. Helier, Jersey JE2 3RG, Channel Islands

**ENDS**

---

#### **About LMA**

Incorporated in the Netherlands Antilles in 1998, LMA listed on the Mainboard of the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ laryngeal mask airway range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ laryngeal mask airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Bonn, Germany, San Diego, California and Melbourne, Australia. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA. For more information, visit [www.lmanv.com](http://www.lmanv.com).